Home / Home

Multiple Myeloma Research

Multiple myeloma research is rapidly evolving with bispecific antibodies, CAR-T cell therapy, and next-generation maintenance strategies.

Our Multiple Myeloma Analysis

  • July 16, 2026New England Journal of MedicineENDURANCE (ECOG-ACRIN E1A11) maintenance randomization (NCT01863550)

    Indefinite Lenalidomide Maintenance Fails to Beat 2-Year Fixed Duration in Myeloma

    Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.

Related topics: Fixed-Duration and De-escalated Therapy